Shots:

• The alliance will validate multiple biomarkers to be used in Thermo Fisher's Oncomine Dx Target Test- which will be used to identify variant-positive patients for enrollment into clinical studies focusing NSCLC and may follow other cancer indications
• The ability of the Oncomine Dx Target test to rapidly detect variants from small quantities of DNA/ RNA samples makes it a focus of multiple drug development and clinical trial support agreements- signed b/w Thermo Fisher and other companies
• Oncomine Dx Target Test is an NGS assay that contains 46 cancer-related biomarkers and a workflow- featuring a fast turnaround time and the lowest sample requirements on the market for the detection of both DNA and RNA variants and has received the US FDA’s approval in 2017

Click here ­to­ read full press release/ article 

Ref: Thermo Fisher | Image: Janssen